Pfizer's tilrekimig meets primary goal in phase 2 eczema trial
Pfizer's experimental eczema drug tilrekimig achieved significantly stronger skin clearance compared to placebo at multiple doses in a mid-stage clinical trial after 16 weeks. The company presented detailed Phase 2 results for the atopic dermatitis treatment.
